Wall Street brokerages expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to post sales of $53.35 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Meridian Bioscience’s earnings, with estimates ranging from $53.23 million to $53.47 million. Meridian Bioscience posted sales of $54.13 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 1.4%. The company is scheduled to report its next earnings report on Thursday, April 26th.

According to Zacks, analysts expect that Meridian Bioscience will report full-year sales of $53.35 million for the current financial year, with estimates ranging from $208.59 million to $220.11 million. For the next fiscal year, analysts anticipate that the firm will report sales of $217.83 million per share, with estimates ranging from $216.75 million to $218.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last released its quarterly earnings data on Thursday, January 25th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. The company had revenue of $52.30 million during the quarter, compared to the consensus estimate of $49.00 million. Meridian Bioscience had a return on equity of 17.09% and a net margin of 10.46%. The firm’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.15 EPS.

VIVO has been the subject of several recent analyst reports. Canaccord Genuity reissued a “hold” rating and issued a $14.00 price objective on shares of Meridian Bioscience in a report on Friday, October 13th. Zacks Investment Research raised Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Thursday, October 5th. One analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $16.00.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Meridian Bioscience by 9.1% in the 2nd quarter. Vanguard Group Inc. now owns 4,018,985 shares of the company’s stock valued at $63,299,000 after acquiring an additional 334,480 shares during the period. Dimensional Fund Advisors LP raised its stake in Meridian Bioscience by 4.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,748,848 shares of the company’s stock valued at $25,008,000 after acquiring an additional 80,877 shares during the period. Bank of New York Mellon Corp raised its stake in Meridian Bioscience by 1.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 871,560 shares of the company’s stock valued at $12,463,000 after acquiring an additional 8,377 shares during the period. Fred Alger Management Inc. raised its stake in Meridian Bioscience by 0.4% in the 2nd quarter. Fred Alger Management Inc. now owns 620,591 shares of the company’s stock valued at $9,774,000 after acquiring an additional 2,200 shares during the period. Finally, Northern Trust Corp raised its stake in Meridian Bioscience by 1.6% in the 2nd quarter. Northern Trust Corp now owns 557,398 shares of the company’s stock valued at $8,780,000 after acquiring an additional 8,886 shares during the period. Institutional investors and hedge funds own 86.87% of the company’s stock.

Meridian Bioscience (VIVO) traded down $0.30 during midday trading on Friday, hitting $15.65. The stock had a trading volume of 218,448 shares, compared to its average volume of 277,741. The firm has a market cap of $681.15, a P/E ratio of 30.69 and a beta of 0.90. The company has a current ratio of 5.85, a quick ratio of 4.04 and a debt-to-equity ratio of 0.30. Meridian Bioscience has a 12 month low of $12.15 and a 12 month high of $16.45.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Monday, February 5th will be paid a $0.125 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 3.19%. The ex-dividend date is Friday, February 2nd. Meridian Bioscience’s dividend payout ratio (DPR) is presently 98.04%.

WARNING: This piece was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/01/31/53-35-million-in-sales-expected-for-meridian-bioscience-inc-vivo-this-quarter.html.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.